Instituto Nacional de Cancerologia (INCan) Mexico
Mexico City, Tlalpan, 14080, Mexico
Location status: Recruiting
Location contact
Marisol Arroyo-Hernández, M.D., M.Sc.
CONTACT
Oscar G Arrieta, M.D., M.Sc.
CONTACT
5556280400 ext. 44001
NCT Number: NCT06535451
This prospective study aims to detect early-stage lung cancer using low-dose computed tomography (LDCT) in Mexicans aged 50 or older who are current or former heavy smokers, non-smokers exposed to significant wood smoke, or diagnosed with COPD. Annual LDCT, spirometry, and serum biomarker tests will be conducted over 3 years, and a follow-up lasting up to 10 years.
Interested in participating?
Request Info50 year and older
All sexes
Observational
Mexico City, Tlalpan, 14080, Mexico
Location status: Recruiting
Marisol Arroyo-Hernández, M.D., M.Sc.
CONTACT
Oscar G Arrieta, M.D., M.Sc.
CONTACT
5556280400 ext. 44001
This prospective cohort study aims to detect lung cancer in early stages using LDCT scans in Mexican individuals aged 50 years or older. Eligible participants comprise current smokers with a history of ≥ 20 pack-years, former smokers who have quit within the past 15 years, non-smokers exposed to wood smoke more than 100 hours/year, or patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).
Secondary objectives include assessing the 10-year mortality rate, the association of lung cancer with immunologic biomarkers, the demographic characterization of participants, the psychological impact of an LC screening program, the histological profiling of positive cases, lung function changes in at-risk individuals, and the clinical staging distribution at diagnosis.
The study will conduct annual LDCT scans, lung function tests (spirometry), anxiety and depression assessments, and serum biomarkers tests over 3 years. Positive LDCT results will adhere to LUNG-RADS guidelines and be managed by a multidisciplinary team. Prevention strategies, including tobacco cessation treatments, will be provided. Follow-up will continue for 5 and 10 years or until an event of completion occurs (cancer diagnosis, end of follow-up, or death).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Eligible participants over fifty years old and one of the next criteria:
Exclusion criteria
Elimination Criteria
Annual LDCT, lung function test (spirometry), anxiety/depression assessments, and serum biomarkers tests over 3 years. Follow-up will continue for 5 and 10 years or until event completion (cancer diagnosis, end of follow-up, or death).
Time frame: Annually over 3-year from inclusion
Assess the number of lung cancer detections after each round of screening.
Time frame: 10-year follow-up or death from lung cancer
Assess lung cancer mortality in participants included in the screening protocol and outside the protocol.
Time frame: 10-year follow-up or death from lung cancer
Asses all-cause mortality related to risk factors at the 3-years of LDCT screening and follow-up
Time frame: Annually over 3-year from inclusion
Assess stage of the disease in patients detected by LDCT screening program
Time frame: Annually over 3-year from inclusion
Assess Inflammatory cytokines
Time frame: Annually over 3-year from inclusion
Assess nodule detection rate, characteristics and outcomes detected at the screening protocol.
Time frame: Annually over 3-year from inclusion
Detect participants with a positive spirometry test that covers COPD diagnosis
Time frame: Annually over 3-year from inclusion
Asses psychological diagnosis (anxiety/depression) related to a lung cancer screening program.
Contact information is provided by the study sponsor or research team.
Instituto Nacional de Cancerologia de Mexico
Other
Lung Cancer Early Detection With Low-dose Computed Tomography in High-risk Individuals: Experience in Mexico
Acronym: DETECTO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07646847
Bladder Cancer, Breast Cancer
Basking Ridge, New Jersey, United States
View Trial DetailsNCT07740239
Brain Diseases, Brain Metastasis
Tampere, Finland
View Trial DetailsNCT06540196
Bronchial Neoplasms, Carcinoma, Bronchogenic
Hamilton, Ontario, Canada
View Trial DetailsNCT06410300
Lung Cancer, Lung Diseases
Columbia, Missouri, United States
View Trial Details